Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Neurobiol Exp (Wars) ; 84(1): 70-79, 2024 Mar 28.
Article in English | MEDLINE | ID: mdl-38587322

ABSTRACT

Hemorrhagic complications may be seen following reperfusion therapy with rtPA and/or thrombectomy after acute ischemic stroke (AIS). Neutrophils, lymphocytes, and platelets have important roles in the inflammatory and immune responses that develop in these patients. We investigated time­dependent changes in blood cells, NIHSS and mRS values according to type of reperfusion therapy in AIS patients who developed cerebral hemorrhage. In AIS patients who underwent rtPA and/or thrombectomy and developed cerebral hemorrhage within the first 24 hours after treatment, leukocyte, neutrophil, lymphocyte, platelet counts and their ratios were recorded on admission, 1st, 3rd, and 7th days. NIHSS values on admission, 3rd days and mRS values on admission, discharge, and the 3rd month were recorded. These values were compared according to the type of reperfusion therapy. Out of 436 AIS patients, rtPA was applied in 50.5%, thrombectomy in 28.2%, and rtPA+thrombectomy in 21.3%. Hemorrhage developed in 25.5% of the patients. Patients treated with thrombectomy had a greater rate of cerebral hemorrhage. Pre­stroke mRS values were lower in all therapy types than mRS scores at discharge and the 3rd month. The NIHSS scores did not differ significantly in 3 days. Depending on the type of reperfusion treatment, there are a few time­dependent significant changes observed in the blood cell counts and ratios. In conclusion, there is a relation between the type of reperfusion therapy and the time­dependent changes in blood cells and ratios as well as mRS scores among AIS patients who have undergone rtPA and/or thrombectomy and developed cerebral hemorrhage.


Subject(s)
Brain Ischemia , Ischemic Stroke , Stroke , Humans , Ischemic Stroke/complications , Ischemic Stroke/therapy , Treatment Outcome , Stroke/complications , Stroke/therapy , Cerebral Hemorrhage/complications , Blood Cells , Reperfusion/adverse effects , Brain Ischemia/complications
2.
Neurol India ; 70(3): 1238-1239, 2022.
Article in English | MEDLINE | ID: mdl-35864677

ABSTRACT

Herein, we report two acute ischemic stroke cases that we used prothrombin complex to reverse the effects of warfarin in order to apply intravenous thrombolytic treatment. To the best of our knowledge, there are only limited amount of cases that prothrombin complex concentrates were applied prior to intravenous thrombolytic treatment administration. As one of the biggest acute stroke clinics in our country, we aim to open a discussion for this treatment to be fully researched and understood.


Subject(s)
Ischemic Stroke , Prothrombin , Anticoagulants/therapeutic use , Fibrinolytic Agents/therapeutic use , Humans , International Normalized Ratio , Retrospective Studies , Vitamin K
3.
J Stroke Cerebrovasc Dis ; 29(8): 105004, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32689579

ABSTRACT

BACKGROUND AND AIMS: Various reactive oxygen radicals and inflammatory mediators emerge in ischemic stroke, and changes occur in the number of leukocytes and platelets. Variations in the counts and ratios of these cells may be related to the early and late course and prognosis of stroke. In this study, the relationship between changes in counts or ratios of neutrophil, lymphocyte, platelet, and National Health Institute Stroke Scale (NIHSS) scores was investigated in patients who presented with an ischemic stroke and treated with recombinant tissue plasminogen activator (rtPA) and/or thrombectomy. METHODS: Changes in neutrophil, lymphocyte, platelet counts; neutrophil-to-leukocyte ratio (NLR), neutrophil-to-lymphocyte ratio, platelet-to-leukocyte ratio (PLR), and platelet-to- lymphocyte ratio between day of admission (day 0), and 1st, 3rd, and 7th days after application of treatment modalities in 296 patients presented with acute ischemic stroke who underwent rtPA within the first 4,5 hours and / or thrombectomy within 6 hours after stroke and the relationship between these changes and the NIHSS (National Health Institute Stroke Scale) scores were evaluated retrospectively. RESULTS: In our study, leukocyte and neutrophil counts were higher on the first day after acute ischemic stroke. Platelet counts decreased on the 1st and 3rd days relative to baseline values. Lymphocyte values decreased on day 1, 3 and 7 compared to day 0. There was a significant increase in neutrophil-to-lymphocyte ratios at day 1 and 3 compared to day 0. On the 7th day, neutrophil-to-lymphocyte ratios were significantly lower. There was an increase in platelet-to-lymphocyte ratios at day 1 compared to day 0. The increase in NLR values was more evident on day 1. The increase in PLR on the 7th day was also significant. The patients who underwent rtPA and/or thrombectomy had significantly lower NIHSS scores at the 72th hour of the stroke compared to the NIHSS values at hospital admissions. A positive correlation was found between NIHSS difference values and neutrophil-to-lymphocyte and platelet-to-lymphocyte percent changes. CONCLUSIONS: There are dynamic changes in platelet, neutrophil, lymphocyte counts and ratios in early period after treatment with rtPA and/or thrombectomy in acute ischemic stroke. Variations in the counts and ratios of these cells may be related to NIHSS, which determines the degree of neurological damage of stroke.


Subject(s)
Blood Platelets , Brain Ischemia/therapy , Disability Evaluation , Fibrinolytic Agents/administration & dosage , Lymphocytes , Neutrophils , Stroke/therapy , Thrombectomy , Thrombolytic Therapy , Tissue Plasminogen Activator/administration & dosage , Adult , Aged , Aged, 80 and over , Brain Ischemia/blood , Brain Ischemia/diagnosis , Brain Ischemia/physiopathology , Female , Fibrinolytic Agents/adverse effects , Humans , Lymphocyte Count , Male , Middle Aged , Platelet Count , Predictive Value of Tests , Recovery of Function , Retrospective Studies , Stroke/blood , Stroke/diagnosis , Thrombectomy/adverse effects , Thrombolytic Therapy/adverse effects , Time Factors , Tissue Plasminogen Activator/adverse effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...